Drugs for bad bugs: confronting the challenges of antibacterial discovery

Payne, D. J.; Gwynn, Michael N.; Holmes, David; Pompliano, David L.

doi:10.1038/nrd2201

Cited by 2,283 publications

(2,145 citation statements)

References 26 publications

Supporting

Mentioning

2,094

Contrasting

Unclassified

Order By: Relevance

“…However, bacteria naturally develop resistance, and contributory factors include: the limited number of therapeutic targets that antimicrobials act on; the greater need due to the demands of modern medicine and aging populations; their misuse and overuse; most importantly, the failure to find new antimicrobials to restock the pipeline [2]. Hence, antimicrobial resistance now constitutes a serious global threat [3].…”

Section: Introductionmentioning

confidence: 99%

Interaction between a cationic bolaamphiphile and DNA: The route towards nanovectors for oligonucleotide antimicrobials

Mamusa

Resta

Barbero³

et al. 2016

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Interaction between a cationic bolaamphiphile and DNA: The route towards nanovectors for oligonucleotide antimicrobials

Mamusa

Resta

Barbero³

et al. 2016

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

show abstract

“…The development of genetic methods that enabled testing of enzyme essentiality appeared to offer a short cut to ensure the value of particular targets. A seminal paper from investigators at GSK in 2007, however, reported that the systematic expression of scores of target proteins and their screening against libraries of hundreds of thousands of compounds yielded absolutely nothing in terms of new antimicrobials (Payne et al 2007). Other companies had been suffering similarly frustrating times and the academic laboratories involved in rather lower-level throughput screening could report the same.…”

Section: Introductionmentioning

confidence: 99%

Emerging paradigms in anti-infective drug design

Barrett

Croft

2014

Parasitology

View full text Add to dashboard Cite

The need for new drugs to treat microbial infections is pressing. The great progress made in the middle part of the twentieth Century was followed by a period of relative inactivity as the medical needs relating to infectious disease in the wealthier nations receded. Growing realisation that anti-infectives are needed in many parts of the world, to treat neglected diseases as well as to combat the burgeoning risk of resistance to existing drugs, has galvanised a new wave of research into anti-microbial drugs. The transfer of knowledge from the Pharmaceutical industry relating to the importance of understanding how to target drugs successfully within the body, and improved understanding of how pathogens interact with their hosts, is driving a series of new paradigms in anti-infective drug design. Here we provide an overview of those processes as an introduction to a series of articles from experts in this area that emerged from a meeting entitled “Emerging Paradigms in Anti-Infective Drug Design” held in London on the 17th and 18th September 2012. The symposium was organised jointly by British Society for Parasitology (BSP) and the Biological & Medicinal Chemistry sector of the Royal Society of Chemistry (RSC) and held at the London School of Hygiene & Tropical Medicine. The symposium set out to cover all aspects of the identification of new therapeutic modalities for the treatment of neglected and tropical diseases. We aimed to bring together leading scientists from all the disciplines working in this field and cover the pharmacology, medicinal chemistry and drug delivery of potential new medicines. Sessions were held on: “Target diseases and targets for drugs”, “Target based medicinal chemistry”, “Bioavailability and chemistry”, “Targeting intracellular microbes”, “Alternative approaches and models”, and “New anti-infectives – how do we get there?”This symposium was organised by Simon Croft (LSHTM) and Mike Barrett (University of Glasgow) for the BSP, and David Alker (David Alker Associates) and Andrew Stachulski (University of Liverpool) for the Biological & Medicinal Chemistry sector of the RSC.

show abstract

“…Although most stakeholders agree that new antibiotics could tackle this unmet medical need, opinions vary on how new antibiotics could be discovered and brought into the market in a cost-effective manner. [1][2][3] Two considerations would probably meet with unanimous consensus: the golden era of antibiotic discovery is gone and it will not be repeated; and genomics, combinatorial chemistry and highthroughput screening do not represent the magic bullet to fill the pipeline with new developmental drug candidates. In this respect, it is important to underline the contribution that natural products, especially those of microbial origin, can provide to antibiotic discovery, as advocated by Demain 4,5 on several occasions.…”

mentioning

confidence: 99%

Antibiotic discovery in the twenty-first century: current trends and future perspectives

Donadio¹,

Maffioli²,

Monciardini³

et al. 2010

J Antibiot

224

126

View full text Add to dashboard Cite

New antibiotics are necessary to treat microbial pathogens that are becoming increasingly resistant to available treatment. Despite the medical need, the number of newly approved drugs continues to decline. We offer an overview of the pipeline for new antibiotics at different stages, from compounds in clinical development to newly discovered chemical classes. Consistent with historical data, the majority of antibiotics under clinical development are natural products or derivatives thereof. However, many of them also represent improved variants of marketed compounds, with the consequent risk of being only partially effective against the prevailing resistance mechanisms. In the discovery arena, instead, compounds with promising activities have been obtained from microbial sources and from chemical modification of antibiotic classes other than those in clinical use. Furthermore, new natural product scaffolds have also been discovered by ingenious screening programs. After providing selected examples, we offer our view on the future of antibiotic discovery.

show abstract

Drugs for bad bugs: confronting the challenges of antibacterial discovery

Cited by 2,283 publications

References 26 publications

Interaction between a cationic bolaamphiphile and DNA: The route towards nanovectors for oligonucleotide antimicrobials

Interaction between a cationic bolaamphiphile and DNA: The route towards nanovectors for oligonucleotide antimicrobials

Emerging paradigms in anti-infective drug design

Antibiotic discovery in the twenty-first century: current trends and future perspectives

Contact Info

Product

Resources

About